Thursday, Jun 1, 2023
English News
  • Hyderabad
  • Telangana
  • Andhra Pradesh
  • India
  • World
  • Entertainment
  • Science and Tech
  • Sport
  • Business
  • ...
    • NRI
    • View Point
    • cartoon
    • Columns
    • Reviews
    • Education Today
    • Property
    • Videos
    • Lifestyle
    • Rewind
E-Paper
  • NRI
  • View Point
  • cartoon
  • Columns
  • Reviews
  • Education Today
  • Property
  • Videos
  • Lifestyle
  • Rewind
Home | News | Astrazeneca Tests Covid Booster Shots Against Beta Variant 2

AstraZeneca tests Covid booster shots against Beta-variant

The booster shot, named AZD2816, will be administered to individuals who have previously been fully vaccinated with two doses of AstraZeneca vaccine/Vaxzervia or an mRNA vaccine, at least three months after their last injection.

By IANS
Updated On - 03:30 PM, Mon - 28 June 21
AstraZeneca tests Covid booster shots against Beta-variant
whatsapp facebook twitter telegram

London: British-Swedish biopharmaceutical firm AstraZeneca has in partnership with the University of Oxford rolled out human trials for booster shots against Beta Covid variant.

The booster shot, named AZD2816, will be administered to individuals who have previously been fully vaccinated with two doses of AstraZeneca vaccine/Vaxzervia or an mRNA vaccine, at least three months after their last injection.

In non-vaccinated individuals, AZD2816 will be given as two doses, four or twelve weeks apart, or given as a second dose following a first dose of AstraZeneca vaccine/Vaxzervia –four weeks apart, the company said in a statement on Sunday.

AZD2816 has been designed using the same adenoviral vector platform as AstraZeneca vaccine/ Vaxzervia, with minor genetic alterations to the spike protein based on the Beta (B1351) variant, first identified in South Africa.

The study aims to enroll 2,250 participants from the UK, South Africa, Brazil and Poland to build immunity against the Beta Covid variant.

“Testing booster doses of existing vaccines and new variant vaccines is important to ensure we are best prepared to stay ahead of the pandemic coronavirus, should their use be needed,” said Professor Sir Andrew J. Pollard, chief investigator and director of the Oxford Vaccine Group, in the statement.

Initial data from the trial is expected later this year and, once available, will be submitted to regulators for assessment as a next-generation booster vaccine and through an expedited regulatory pathway, the company said.

“The Beta variant vaccine contains 10 changes across the spike protein, many of which are also seen in other variants of concern, and which lead to effects such as, reduced ability of antibodies induced against the original virus to block cell entry (K417N, E484K, N501Y), increased infectivity compared to the original virus (D614G); reduced sensitivity of neutralising antibodies to the original virus (L452R),” the company said.

Besides these minor modifications, the two AZD2816 and AstraZeneca vaccine/ Vaxzervia vaccines are the same, it noted.

In May, the UK launched a clinical trial that aimed to assess the efficacy of a third ‘booster’ dose of seven different Covid-19 vaccines — Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, Novavax, Valneva, Janssen and Curevac — on patients immune responses.

It costs 19.3 million pound and is being funded by the UK government and led by the University Hospital Southampton NHS Foundation Trust.

Meanwhile, the US Centers for Disease Control and Prevention has noted that there is currently no data to support that a Covid-19 vaccine booster shot is needed for the general population. But, an extra dose may be needed for more-vulnerable groups, such as older adults or organ transplant patients.

Both Pfizer and Moderna are investigating a third dose of Covid vaccine, while Johnson & Johnson is studying the need for a second dose to raise protection against the virus, the report said.

The US NIH’s National Institute of Allergy and Infectious Disease, or NIAID, is also conducting a clinical trial to understand whether a third shot of a Moderna vaccine could be given after a person initially received two shots of Pfizer, or one shot of Johnson & Johnson, the report added.

  • Follow Us :
  • Tags
  • AstraZeneca
  • biopharmaceutical firm
  • British-Swedish
  • Covid variant

Related News

  • Oxford graduate’s heart-warming note about her late grandfather goes viral

    Oxford graduate’s heart-warming note about her late grandfather goes viral

  • COVID-19 vaccines don’t cause monkeypox, shingles: Experts

    COVID-19 vaccines don’t cause monkeypox, shingles: Experts

  • Covid variant worse than Omicron in next two years: UK epidemiologist

    Covid variant worse than Omicron in next two years: UK epidemiologist

  • India’s Omicron tally closer to 5000 cases

    India’s Omicron tally closer to 5000 cases

  • Boosters can wane, 4th Covid shot may be necessary: Moderna CEO

    Boosters can wane, 4th Covid shot may be necessary: Moderna CEO

  • New Covid variant detected in France not a threat yet: WHO

    New Covid variant detected in France not a threat yet: WHO

Latest News

  • WhatsApp launches global security centre to further safeguard users

    10 mins ago
  • Jagan to credit first phase of YSR Rythu Bharosa-PM Kisan Yojana on Thursday

    11 mins ago
  • Five died, including a minor, in separate accidents in Khammam

    16 mins ago
  • Our fight is ours, not seeking any international support: Rahul Gandhi at Stanford

    27 mins ago
  • YS Vivekananda Reddy murder: Telangana HC grants anticipatory bail to Avinash Reddy

    37 mins ago
  • Commercial LPG cylinder prices slashed by Rs 83.5; domestic unchanged

    56 mins ago
  • French Open: Novak Djokovic reaches 3rd round after defeating Fucsovics

    1 hour ago
  • Three from Telangana die in road accident in Tirupati

    1 hour ago

company

  • Home
  • About Us
  • Contact Us

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

© Copyrights 2022 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam